title: Emerging pharmacotherapies for diabetic macular edema.
abstract: Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.
authors.affiliation: Department of Ophthalmology, Baylor College of Medicine, 7200-B Cambridge Street, Houston, TX 77030, USA.
authors.forename: Golnaz
authors.initials: G
authors.lastname: Javey
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Schwartz
authors.forename: Harry W
authors.initials: HW
authors.lastname: Flynn
mesh_terms: D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D014792:Visual Acuity / Q000187:drug effects